K.Vita: a feasibility study of a blend of medium chain triglycerides to manage drug-resistant epilepsy

Natasha E. Schoeler,1,2,* Michael Orford,1,* Umesh Vivekananda,3,4 Zoe Simpson,2 Baheerathi Van de Bor,2 Hannah Smith,2 Simona Balestrini,4,5 Tricia Rutherford,6 Erika Brennan,6 James McKenna,6 Bridget Lambert,6 Tom Barker,6 Richard Jackson,7 Robin S. B. Williams,5 Sanjay M. Sisodiya,4,5 Simon Eaton,1 Simon J. R. Heales,1,2,3,4,* J. Helen Cross,1,* Matthew C. Walker3,4,* and K.Vita Study Group

* These authors contributed equally to this work.

This prospective open-label feasibility study aimed to evaluate acceptability, tolerability and compliance with dietary intervention with K.Vita, a medical food containing a unique ratio of decanoic acid to octanoic acid, in individuals with drug-resistant epilepsy. Adults and children aged 3–18 years with drug-resistant epilepsy took K.Vita daily whilst limiting high-refined sugar food and beverages. K.Vita was introduced incrementally with the aim of achieving 35% energy requirements for children or 240 ml for adults. Primary outcome measures were assessed by study completion, participant diary, acceptability questionnaire and K.Vita intake. Reduction in seizures or paroxysmal events was a secondary outcome. 23/35 (66%) children and 18/26 (69%) adults completed the study; completion rates were higher when K.Vita was introduced more gradually. Gastrointestinal disturbances were the primary reason for discontinuation, but symptoms were similar to those reported from ketogenic diets and incidence decreased over time. At least three-quarters of participants/caregivers reported favourably on sensory attributes of K.Vita, such as taste, texture and appearance, and ease of use. Adults achieved a median intake of 240 ml K.Vita, and children 120 ml (19% daily energy). Three children and one adult had β-hydroxybutyrate >1 mmol/l. There was 50% (95% CI 39–61%) reduction in mean frequency of seizures/events. Reduction in seizures or paroxysmal events correlated significantly with blood concentrations of medium chain fatty acids (C10 and C8) but not β-hydroxybutyrate. K.Vita was well accepted and tolerated. Side effects were mild and resolved with dietetic support. Individuals who completed the study complied with K.Vita and additional dietary modifications. Dietary intervention had a beneficial effect on frequency of seizures or paroxysmal events, despite absent or very low levels of ketosis. We suggest that K.Vita may be valuable to those with drug-resistant epilepsy, particularly those who cannot tolerate or do not have access to ketogenic diets, and may allow for more liberal dietary intake compared to ketogenic diets, with mechanisms of action perhaps unrelated to ketosis. Further studies of effectiveness of K.Vita are warranted.

1 UCL Great Ormond Street Institute of Child Health, London, UK
2 Great Ormond Street Hospital for Children, London, UK
3 National Hospital for Neurology and Neurosurgery, London, UK
4 UCL Queen Square Institute of Neurology, London, UK
5 Chalfont Centre for Epilepsy, Chalfont-St-Peter, UK
6 Vitaflo (International) Ltd, Liverpool, UK
7 University of Liverpool, Liverpool, UK
8 Department of Biological Sciences, Royal Holloway University of London, Surrey, UK

Received March 03, 2021. Revised May 18, 2021. Accepted May 25, 2021
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Ketogenic diets (KDs) are high-fat, low-carbohydrate diets, and are the management option of choice for certain neurometabolic disorders and an effective treatment option for individuals with drug-resistant epilepsy.\(^1\) Despite their efficacy, the stringent dietary restriction of KDs greatly impacts patients and their carers. Medium chain triglycerides (MCTs) enable decreased fat and increased protein and carbohydrate intake compared to...
long chain triglyceride–based KDs, although MCTs may be unacceptable due to their oily taste and distinctive mouth and throat feel. MCT products can be flavoured or incorporated into recipes to enhance palatability, but this may be inconvenient and time-consuming.

The canonical view of the mechanism of action of KDs is through ketone production, despite the lack of correlation of ketone levels with seizure reduction. This has driven increasing interest in the role of MCT-derived fatty acids, in particular decanoic acid (C10). C10 is able to cross the blood–brain barrier and decreases excitatory neurotransmission and network excitability in vitro, increases seizure threshold in mice, and increases mitochondrial number plus respiratory chain and catalase activity. These effects may be potentiated by C8, which spares C10 from oxidation in neuronal-like cells.

This potentially beneficial effect of C10 on energy metabolism and network excitability, in combination with improved palatability of MCT, may offer a simplified approach to dietary management of epilepsy. K.Vita contains a higher proportion of C10 to C8 (80:20) than currently available medical foods (generally 40:60 C10:C8). This trial aimed to evaluate compliance, acceptability, tolerability and biochemical impact of K.Vita in the dietary management of individuals with drug-resistant epilepsy.

Materials and methods

Ethics

Favourable ethical opinion for this single-arm, prospective feasibility study was granted by London—City & East Research Ethics Committee (15/LO/1979). Written informed consent was obtained from all participants (or their carers) in the study. The study was registered with Clinicaltrials.gov (NCT02825745).

Study product

K.Vita is a ready-to-use, palatable thickened flavoured liquid containing 80:20 C10:C8 triglyceride, in 120 ml packets.

Sponsor

This study was funded by Vitaflo (International) Ltd. The sponsor created, produced and distributed K.Vita and were involved in the concept and study design, analysis of data and reviewing the manuscript. They were not involved in data collection, the writing of the initial manuscript or the decision to submit the manuscript for publication.

Participants

A target sample size of 40 children and 40 adults was determined on the basis of obtaining sufficient information to perform reliable sample size estimates for future later phase studies. Participants were adults, aged >18, and children aged 3–18 years (under 3 s were excluded owing to Foods for Special Medical Purposes regulations) with epileptic seizures, or associated paroxysmal non-epileptic events (for individuals with glucose transporter type 1 deficiency syndrome (GLUT1-DS) or Alternating Hemiplegia of Childhood (AHC), despite adequate levels of antiseizure medicines (ASMs). Children had a clinical or genetic diagnosis of Dravet syndrome or another early-onset epilepsy resulting from a confirmed or presumed genetic mutation. Inclusion criteria were absence of medical conditions that contra-indicated use of MCT, for example, medium-chain acyl-coenzyme A dehydrogenase deficiency; participant and/or parent/guardian able to comply with the study protocol; written, informed consent. Exclusion criteria were children <3 years old; freedom from seizures or paroxysmal events for >4 weeks at the time of recruitment; currently following a KD; females who were pregnant or planning to become pregnant during the study.

Setting

Potential participants were identified by their consultants during routine epilepsy clinics at Great Ormond Street Hospital for Children (GOSH, London, UK), The National Hospital for Neurology and Neurosurgery (London, UK) and The Chalfont Centre for Epilepsy (Chalfont-St-Peter) from June 2016 to March 2018.

Schedule of events

The study consisted of three visits (A, B and C): baseline, 5 and 12 weeks after starting K.Vita, plus regular telephone or email contact. At visit A, the target amount of K.Vita was determined, dependent on participant age. For children, this was a maximum of 17.5% daily energy requirements by visit B and 35% daily energy requirements, or two packets, by visit C. The target amount for adults was a maximum of one packet daily by visit B and two packets daily by visit C. K.Vita was introduced incrementally, according to gastrointestinal (GI) tolerance. A protocol amendment (May 2017) allowed greater flexibility in the speed of introducing K.Vita (no maximum amount of time was set, whereas prior to the amendment introduction was generally over one week) and amount taken (clarification that the maximum daily amounts were not a target to be reached). The amount was divided into three or four equal servings, taken at regular intervals daily, as part of a meal, snack or enteral feed. When taken orally, K.Vita was consumed unadulterated, or mixed into cordial or food such as yogurt. When taken via feeding tube, it was administered either immediately before or after, or mixed into, an enteral feed, with a water flush directly after administration.

Participants and/or parent/guardians were given guidance on excluding high-refined sugar foods and beverages, such
as sweetened drinks, fruit juice, confectionary and breakfast cereals, to balance the additional calories from K.Vita, if appropriate, and to optimize the nutritional quality of the participant’s diet. Starchy carbohydrates, such as bread, pasta, rice and potatoes, were not restricted. If tube fed, participants kept their usual enteral feed/regime, with adjustments to balance the calories from K.Vita if necessary. If there was concern about the nutritional adequacy of a participant’s diet during the study, dietary advice was given and/or a daily micronutrient supplement was started. K.Vita tolerance was reviewed and daily intake adjusted, as appropriate. A daily record was kept of K.Vita intake, GI symptoms and frequency of seizures or paroxysmal events. No changes were made to concurrent medications, unless advised by the investigator for severe seizure escalations.

At each visit, anthropometric measures, 3-day diet history and seizure review were undertaken. At visit C, participants and/or parent/guardians completed an acceptability questionnaire relating to their experience of using K.Vita. The option was given to continue K.Vita; participants then received their usual care, as provided pre-study.

**Biochemical blood and urine analysis**

Biochemical blood and urine analysis was performed at all visits to assess patient suitability and monitor clinical safety. Samples were analysed at GOSH or UCL Great Ormond Street Institute of Child Health. Plasma levels of free medium chain fatty acids and β-hydroxybutyrate (BHB) were measured at all visits by negative ion chemical ionization gas chromatography mass spectrometry or positive ion chemical ionization gas chromatography mass spectrometry, respectively.

**Statistical analysis**

The main outcomes of the feasibility study were tolerability, acceptability and compliance with K.Vita, assessed via the metrics of: number of patients to withdraw from the study, number of adverse events reported throughout the study, participant comments on appearance, taste, flavour preference, texture, ease of consumption, ease of use, method of use, packaging and presentation of K.Vita, number of patients to discontinue or reduce K.Vita intake, total quantity of K.Vita consumed, and proportion of daily calories from K.Vita consumed compared to starch, sugar, protein and fat intake from dietary intake. Continuous data were described as mean or median [interquartile range (IQR)] and categorical data were presented as frequencies of counts with associated percentages.

Data on seizure/paroxysmal event frequency in the first, second and third 4-week blocks of the study were modelled using repeated measures random effects modelling, adjusting for data source (study diary or physician- documented count) and patient age (child versus adult) as fixed effects, and participant identifier as a random intercept. Regression modelling included baseline seizure/event rate as an adjusting covariate with seizure/event counts modelled on the log + c scale. The rate of seizures was modelled on the log + 0.5 scale following inspection of the model residuals. Sensitivity analyses were performed discounting patients who changed dose or number of ASMs taken during the intervention period and to account for changes to the study protocol.

Plasma C8, C10 and BHB levels were compared using Mann–Whitney test. Correlation between biochemistry parameters was assessed using Spearman’s rank correlation. Associations between biomarker data and seizure/event rates were explored by including the biomarker expression data as a fixed effect in the random effects model. Plasma C10 and seizure/event frequency were transformed using a log(x + c) transformation. Plasma C8 was not included in the model owing to multicollinearity. All analyses were conducted using R: A Language and Environment for Statistical Computing (Version 3).

**Data availability**

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

**Results**

Seventy-seven individuals were consented, of whom 61 (35 children, 26 adults; 59% female) started K.Vita (Fig. 1; Table 1). The children had refractory genetic epilepsies, AHC or GLUT1-DS, and the adults had mainly focal epilepsies (Table 1), all of whom had failed multiple ASMs: median 3 ASMs (IQR: 4–7) for children and median 10 ASMs (IQR: 8–15) for adults, who completed the trial.

Of the 61 participants who started K.Vita, 20 (33%, 19 children and 1 adult) had previously been on a KD. Of these 20, 9 (45%) had stopped the KD for personal or social reasons, predominantly due to patient and/or caregiver non-compliance, 7 (35%) due to lack of efficacy, 2 (10%) as they had been on the diet for >2 years, and 2 (10%) due to unknown reasons. Of those who started K.Vita, 7/35 (20%) children and 4/26 (15%) adults had been previously referred for KD treatment but did not start owing to clinical concerns, social circumstances or caregiver apprehension about what the KD entailed. Of 26 adults, 21 (81%) had no access to KD services.

Sixty-six per cent (23/35) of children and 69% (18/26) of adults completed the trial (Fig. 1), giving an overall withdrawal rate of 20/61 (33%). The most common reasons for withdrawal were GI side effects—predominantly abdominal pain/discomfort, diarrhoea and/or vomiting—reported by 5/12 (42%) children and 6/8 (75%) adults,
who discontinued. Other reasons for discontinuation (some participants reported multiple reasons) were behaviour change \((n=2\) children), reduced appetite \((n=1\) child), possible exacerbation of seizures \((n=1\) child and \(n=1\) adult), sore throat \((n=2\) adults), lack of clinical effectiveness \((n=1\) child and \(n=1\) adult) and unknown/lost to follow-up \((n=4\) children and \(n=1\) adult).

Exploratory analyses of the impact of a protocol amendment, which altered the speed of introduction of K.Vita, showed that the number of participants withdrawing from the study due to adverse events reduced from 32\% \((14/38)\) under the initial protocol to 18\% \((3/17)\) in the revised protocol. The proportion of participants who started K.Vita but then withdrew from the study due to any reason reduced from 36\% \((16/38)\) under the initial protocol to 24\% \((4/17)\) in the revised protocol.

Ninety-one per cent \((21/23)\) of children and 56\% \((10/18)\) of adults who completed the study, chose to remain on K.Vita post-study. Those who declined to remain on K.Vita did so due to perceived lack of clinical effectiveness.

**Tolerability**

The most frequently reported GI symptoms were abdominal bloating/feeling full, excessive flatulence and constipation (Table 2). GI symptoms peaked during the introduction period, then tended to decrease. There was a peak in instances of diarrhoea in weeks 11 and 12, primarily due to two participants (seemingly unconnected to K.Vita for one participant and unknown for the other). Non-GI reported adverse side effects, considered to be possibly, probably or highly probably related to K.Vita were infrequent (25 reports in total) and most (72\%) were mild in severity (Table 3).

Prior to the protocol amendment, participants reported a greater degree of nausea, abdominal bloating and abdominal pain than those who entered into the study following the amendment. Conversely, those who entered under the amended recommendations showed greater amounts of excessive flatulence and constipation.
Acceptability

Of 15 caregivers and 19 adults who returned the acceptability questionnaire, 84% agreed/strongly agreed that K.Vita had good flavour and taste, 88% liked the appearance and colour of K.Vita, 77% liked the texture, mouthfeel and consistency of K.Vita, and 88% agreed/strongly agreed that it was easy to take K.Vita and to follow advice about reducing sugar intake. One-third of adults felt that K.Vita was helpful for their epilepsy, compared to two-thirds of caregivers.

Compliance

Eighty-seven per cent (41/47) of participants complied with the recommended amount of K.Vita at visit B [median (IQR) = 84.5 ml (60–100) or 15% total energy for children, and 120 ml (120–120) for adults]; 28/38 (74%) complied at visit C [median (IQR) = 120 ml (90–180) or 19% total energy for children and 240 ml (240–240) for adults].

In the 22/23 (96%) children for whom data are available for visits B and C, the median (IQR) intake of

Table 1

Demographic data and baseline characteristics of participants who started K.Vita

| Participants starting K.Vita (total n = 61) | Sex (self-reported), n (%): 36 (59%) Female | 25 (41%) Male |
| Age (years): Mean 21.1 | Median 15.7 |
| Min, Max 2.8, 68 |
| Age categories (years), n (%): 3–18 35 (56%) | ≥18 26 (44%) |
| Ethnicity, n (%): Asian or Asian British 3 (5%) | Mixed Race 3 (5%) |
| Black or Black British 3 (5%) | Other 1 (2%) |
| Caucasian 51 (84%) |
| Epilepsy syndrome/diagnosis—children: Dravet syndrome 8 (23%) | Genetic epilepsy (Other) 13 (37%) |
| Presumed genetic epilepsy 6 (17%) | Alternating Hemiplegia of Childhood (AHC) 5 (14%) |
| GLUT1 deficiency syndrome 3 (9%) |
| Epilepsy syndrome/diagnosis—adults: Focal epilepsy 15 (58%) | Genetic generalized epilepsy 6 (23%) |
| GLUT1 deficiency syndrome 1 (4%) | Unknown 4 (15%) |

Table 2

Number of reports of gastrointestinal symptoms in study cohort

| Symptom reports in cohort, n = 39a | Weeks 1–4 | Weeks 5–8 | Weeks 9–12 |
|-----------------------------------|-----------|-----------|-----------|
| Vomiting                          | Median (IQR) | Highest number of reports per person | Median (IQR) | Highest number of reports per person | Median (IQR) | Highest number of reports per person |
| Nausea                            | 0 (0–0) | 6 | 0 (0–0) | 2 | 0 (0–0) | 6 |
| Abdominal bloating/feeling full   | 0 (0–2) | 28 | 0 (0–0) | 28 | 0 (0–0) | 25 |
| Abdominal pain/discomfort         | 1 (0–6) | 18 | 0 (0–1) | 18 | 0 (0–0) | 15 |
| Excessive burping                 | 0 (0–0) | 13 | 0 (0–0) | 5 | 0 (0–0) | 1 |
| Excessive flatulence               | 0 (0–2) | 24 | 0 (0–0) | 28 | 0 (0–0) | 21 |
| Diarrhoea                         | 0 (0–1) | 10 | 0 (0–0) | 14 | 0 (0–1) | 14 |
| Constipation                      | 0 (0–0) | 20 | 0 (0–0) | 28 | 0 (0–0) | 21 |

Table 2a Number of reports of gastrointestinal symptoms in study cohort

*One child started prior to third birthday due to current clinical state, at the discretion of the investigator.
*Includes mutations in PCHD19 (n = 2), SCN1A not associated with Dravet Syndrome (n = 2), CHD2, CDKL5, ALG13, SCNBA, KCNA2 and FBXL4, tetrasomy 18p10, translocation between chromosomes 3 and 9, and Ch9q22 deletion.

Table 2

Number of reports of gastrointestinal symptoms in study cohort

| Symptom reports in cohort, n = 39a | Weeks 1–4 | Weeks 5–8 | Weeks 9–12 |
|-----------------------------------|-----------|-----------|-----------|
| Vomiting                          | Median (IQR) | Highest number of reports per person | Median (IQR) | Highest number of reports per person | Median (IQR) | Highest number of reports per person |
| Nausea                            | 0 (0–0) | 6 | 0 (0–0) | 2 | 0 (0–0) | 6 |
| Abdominal bloating/feeling full   | 0 (0–2) | 28 | 0 (0–0) | 28 | 0 (0–0) | 25 |
| Abdominal pain/discomfort         | 1 (0–6) | 18 | 0 (0–1) | 18 | 0 (0–0) | 15 |
| Excessive burping                 | 0 (0–0) | 13 | 0 (0–0) | 5 | 0 (0–0) | 1 |
| Excessive flatulence               | 0 (0–2) | 24 | 0 (0–0) | 28 | 0 (0–0) | 21 |
| Diarrhoea                         | 0 (0–1) | 10 | 0 (0–0) | 14 | 0 (0–1) | 14 |
| Constipation                      | 0 (0–0) | 20 | 0 (0–0) | 28 | 0 (0–0) | 21 |

*Number of participants who returned study diaries.

Compliance

Eighty-seven per cent (41/47) of participants complied with the recommended amount of K.Vita at visit B [median (IQR) = 84.5 ml (60–100) or 15% total energy for children, and 120 ml (120–120) for adults]; 28/38 (74%) complied at visit C [median (IQR) = 120 ml (90–180) or 19% total energy for children and 240 ml (240–240) for adults].

In the 22/23 (96%) children for whom data are available for visits B and C, the median (IQR) intake of
K.Vita was 90.5 ml (63.75, 100) at visit B and 120 ml (90, 180) at visit C. Overall, 18/22 (82%) increased intake between the two visits, 2/22 (9%) had no change and 2/22 (9%) reduced their intake. In the 16/18 (89%) adults for whom data are available for visits B and C, a median (IQR) intake of 120 ml (120, 120) was observed at visit B and 240 ml (230, 240) at visit C. 14/18 (89%) increased intake between the two visits, 1/18 (6%) showed no change and 1/18 (6%) reduced intake. A total of 6/40 (15%) participants reduced K.Vita intake or discontinued prior to visit C.

### Assessment of daily energy and macronutrient intakes

Four children were partially or totally enterally fed and were successfully given K.Vita via their feeding tubes. Mean daily energy intake was 1452 kcal (range 532–2941 kcal, n = 34) for children and 1446 kcal (range 676–2263 kcal, n = 26) for adults at visit A; 1788 kcal (range 788–4097 kcal, n = 29) for children and 1981 kcal (range 1419–3277 kcal, n = 22) for adults at visit B; 2009 kcal (range 992–3367 kcal, n = 22) for children and 2167 kcal (range 1113–3276 kcal, n = 26) for adults at visit C.

Mean energy from dietary fat remained stable from visits A to C: 41% daily energy at both visits in children and 42% to 38% daily energy in adults; K.Vita provided an additional mean 15% daily energy at visit B and 18% at visit C in children, and 18% daily energy at visit B and 24% at visit C in adults (Fig. 2). In accordance with study guidelines, intake of sugar decreased following visit A in children and adults (Fig. 2).

The mean proportion of energy from protein decreased from visits A to C (Fig. 2), although actual mean daily intakes for children remained stable (mean 52.9 g at visit A; 53.9 g at visit C). For adults, mean daily intakes reduced by 1.8 g (mean 51.4 g at visit A; 49.6 g at visit C).

Eighty-six per cent (18/21) of children met their daily Average Requirement (AR), and/or Population Reference Intake for protein throughout the study. Sixty-nine per cent (11/16) of adults met their daily AR for protein (0.66 g/kg/day), which was no different to baseline.

### Anthropometry

There was no significant change in body weight (mean change +1.57 kg, range -3.0 to +10.8 kg in children; -0.41 kg, range -4.6 to +4.7 kg in adults) or body mass index (BMI) (z-scores -0.21, range -1.5 to +0.45 for children; mean change +0.1 kg/m², range -2.2 to +3.3 kg/m² for adults). Weight loss of 4.6 kg was observed in one adult with a baseline BMI 33.1 kg/m²; weight gain of 4.7 kg was observed in another adult with a baseline BMI 18.2 kg/m². In both cases, weight change was desired and clinically appropriate. One child with GLUT1-DS gained 10.8 kg (+14 percentiles, UK-World Health Organization growth charts), due to greater range and quantity of foods available, following recent discontinuation of the KD. Reported energy intake confirmed this and dietetic guidance was provided.

### Table 3 Number of reports and severity of non-gastrointestinal adverse side effects during the study period

| Adverse side effect | Number of reports classified as ‘Mild’ | Number of reports classified as ‘Moderate’ | Number of reports classified as ‘Severe’ | Total number of reports |
|---------------------|---------------------------------------|------------------------------------------|----------------------------------------|-------------------------|
| Mood swings/behavioural change | 2 | 1 | – | 3 |
| Sore throat | 3 | – | – | 3 |
| Decreased appetite | 1 | 1 | – | 2 |
| Fatigue | 1 | – | – | 1 |
| Amenorrhea | 1 | – | – | 1 |
| Bed wetting | 1 | – | – | 1 |
| Increase in biting episodes | – | 1 | – | 1 |
| Cramps | – | 1 | – | 1 |
| Dizziness | 1 | – | – | 1 |
| Food phobia | – | 1 | – | 1 |
| Headache | – | – | 1 | 1 |
| Heartburn | 1 | – | – | 1 |
| Hypoglycaemic event | 1 | – | – | 1 |
| Itchy skin | 1 | – | – | 1 |
| Pain on urination | 1 | – | – | 1 |
| Pale stools | 1 | – | – | 1 |
| Possible seizure exacerbation | 1 | – | – | 1 |
| Reflux | 1 | – | – | 1 |
| Small red patches on face on consumption of un-flavoured version of K.Vita | 1 | – | – | 1 |

Medium chain triglycerides for epilepsy
Biochemistry

There were no significant changes in routine biochemical parameters from baseline to visit C (Table 4), nor any changes that were deemed clinically significant, independent of whether participants completed the trial or not.

Most participants exhibited a very mild yet significant increase in plasma BHB throughout the trial [median (range) 0.07 (0.05–0.22) mmol/l at visit A and 0.22 (0.05–1.13) mmol/l at visit C in adults; 0.095 (0.05–1.94) mmol/l at visit A and 0.26 (0.05–3.02) mmol/l at visit C in children, Fig. 3]. Only three children (17%) and one adult (7%) became ‘ketotic’ (BHB > 1 mmol/l); 5 children (28%) and 2 adults (15%) had BHB > 0.5 mmol/l. C8 and C10 fatty acid levels increased significantly from baseline to visit C, with adults showing a less pronounced increase [median (range) 42.3 (9.4–101.8) mmol/l C8 and 165.1 (18.3–407.4) mmol/l C10 at visit C; Fig. 3]. The relative contribution of C8 and C10 to the free fatty acid pool increased from 3.2 ± 2.8% at baseline to 37.7 ± 14.2% at visit C. At visit C, C10 accounted for mean 77.0 ± 10.0% and C8 mean 23.0 ± 10% of the total medium chain fatty acids in blood, consistent with the 80:20 C10: C8 ratio in K.Vita.

Clinical efficacy

Thirty-nine per cent (9/23) of children and 56% (10/18) of adults who completed the study returned the study diaries with quantifiable records of seizures or (for one individual with GLUT1-DS and one individual with AHC) paroxysmal non-epileptic events. Physician-documented seizure/event counts were reviewed for all others; four children had insufficient data to allow for quantification of seizures.

Thirty-eight per cent (6/16) (38%) of children and 50% (8/16) of adults achieved ≥50% seizure or event reduction. Some syndromes seemed to respond particularly well: both children with AHC, who completed the trial, had ≥50% reduction in seizures/paroxysmal events; one child with GLUT1-DS and gait difficulties, but without current seizures, became free of paroxysmal events.

The estimated mean rate of seizures or paroxysmal events in children and adults was 14.31 at visit A (weeks 1–3), 9.12 at visit B and 7.22 at visit C: overall there was a 50% (95% CI 39–61%) reduction in seizures/events between visits A and C. This was a statistically significant reduction in estimated number of seizures/events from visits A–B (Z = −3.399, P = 0.001) and visits A–C (Z = −5.122, P < 0.001), adjusting for the source of data (diary versus physician documentation), patient age and study visit (Fig. 4).

None of the sensitivity analyses, excluding participants with seizure data who changed dose or number of ASMs within the intervention period (n = 7), and comparing participants who started prior to (n = 43) or after the protocol amendment (n = 13), had any substantive impact on the interpretation of the study results (Supplementary Table 1).

Association of clinical response with biochemical parameters

Plasma C10 concentration negatively correlated with seizure/event frequency (P < 0.0001). Plasma C8 and C10 were highly correlated (Pearson’s R² 0.87), and plasma BHB was weakly correlated with C8 (R² 0.19), C10 (R² 0.21) and C8:C10 ratio (R² 0.01). There was no significant association between plasma BHB concentrations and seizure/event frequency (χ² = 0.0793, P = 0.778).

Discussion

This open-label trial showed that K.Vita, when introduced gradually in accordance to individual tolerance, was favourably accepted in our cohort alongside minimal dietary modification. Adverse side effects were predominantly mild and resolved with dietetic support. Adults who completed the study were, on average, able to comply with the daily target amount; most children better...
tolerated lower amounts. Although the study was uncontrolled and not designed to determine clinical response, mean frequency of seizures/paroxysmal events was significantly reduced, despite low levels or absence of ketosis and the fact that seizure frequency was only documented significantly reduced, despite low levels or absence of ketosis and the fact that seizure frequency was only documented from the time of introduction.

The target amount of MCT from K.Vita was based on the minimum percentage of daily energy requirements known to be efficacious in the MCT KD.4 GI symptoms experienced in this study are commonly associated with MCT15 and were no different to those reported in individuals following KDs.16 GI symptoms from K.Vita, decreased over time and were mitigated by phased introduction, which is not always the case for KDs. For example, 33–45% children following KDs suffer constipation during the first 3 months, and these high rates continue thereafter, irrespective of whether a classical or MCT KD is followed17; in our study, reported incidences of constipation declined by the end of 12 weeks. Other adverse effects were infrequent, mostly non-specific and likely unrelated to K.Vita. Attrition rates due to adverse effects in our study were low after greater flexibility was allowed with the time-scale for K.Vita introduction and quantity taken. At all stages, scheduled contact with the dietitian to provide support, advice and encouragement, helped reduce the incidence of GI side effects, and prevented early discontinuation. In randomized controlled studies of children and adults on KDs,18 diet discontinuation rates prior to 3 months are as high as 55%.

The majority of participants or caregivers in our study reported favourably on the sensory attributes of K.Vita and ease of use in conjunction with minimal dietary restriction. In contrast, reported grievances from individuals who have commenced a KD include issues with food preparation and restricted choices,19 approximately half of adults and 20% of children have discontinued dietary treatment, sometimes despite clinical effectiveness, owing to the intense effort required for food selection and preparation, social restrictions or refusal to comply with the diet.20,21 The restraints of conventional KDs may deter people from starting dietary treatment, with only 14–30% of successfully screened adult patients enrolling in dietary trials.20 This is reflected in our cohort who started K.Vita, of whom almost half who had previously been on a KD had discontinued it due to personal or social reasons, including non-compliance, and almost 20% were offered KD but chose not to start. Such issues are likely to be overcome with the use of K.Vita in this specific population.

| Table 4 Biochemical parameters measured at baseline and visit C (study completers only) |
|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| **Children**                        | **Adults**                          | **Children**                        | **Adults**                          |
| **Visit A**                         | **Visit C**                         | **Visit A**                         | **Visit C**                         |
| **Mean (range)**                    | **Mean (range)**                    | **Mean (range)**                    | **Mean (range)**                    |
| Glucose (mmol/l)                    | 4.3 (2.8–5.7)                       | 4.3 (3.1–6.4)                       | 4.5 (3.6–5.8)                       |
| Triglycerides (mmol/l)              | 1.18 (0.53–3.80)                    | 1.35 (0.54–3.91)                    | 1.3 (0.46–3.83)                     |
| NEFA (mmol/l)                       | 0.55 (0.17–1.03)                    | 0.62 (0.20–1.19)                    | 0.4 (0.08–1.03)                     |
| Cholesterol (mmol/l)                | 4.1 (3.0–5.2)                       | 4.2 (0.7–5.3)                       | 5.2 (3.9–7.6)                       |
| Urea (mmol/l)                       | 4.8 (2.6–7.0)                       | 4.3 (1.9–7.3)                       | 4.8 (2.8–7.6)                       |
| Creatinine (µmol/l)                 | 49223–86                            | 46 (22–69)                          | 74 (59–93)                          |
| Sodium (mmol/l)                     | 142 (138–148)                       | 142 (138–146)                       | 142 (135–146)                       |
| Potassium (mmol/l)                  | 4.4 (3.5–7.0)                       | 4.5 (3.4–7.1)                       | 4.1 (3.5–7.0)                       |
| ALT (U/l)                           | 22 (9–32)                           | 25 (14–36)                          | 30.4 (8–64)                         |
| ALP (U/l)                           | 157 (61–266)                        | 150 (85–271)                        | 77.3 (40–124)                       |
| Bilirubin (µmol/l)                  | 8 (0–13)                            | 7 (4–12)                            | 10.1 (4–15)                         |
| Albumin (g/l)                       | 44 (37–51)                          | 44 (39–50)                          | 45.4 (36–51)                        |
| Urate (µmol/l)                      | 249 (98–405)                        | 275 (139–420)                       | 274.3 (102–488)                     |
| Total CO2 (mmol/l)                  | 23 (18–29)                          | 23 (16–27)                          | 28 (20–33)                          |
| Calcium (mmol/l)                    | 2.35 (2.15–2.53)                    | 2.36 (2.16–2.58)                    | 2.4 (2.2–2.69)                      |
| Magnesium (mmol/l)                  | 0.90 (0.81–1.03)                    | 0.89 (0.78–1.01)                    | 0.90 (0.74–0.98)                    |
| Phosphate (mmol/l)                  | 1.49 (1.02–1.86)                    | 1.42 (0.97–1.82)                    | 1.2 (0.97–1.82)                     |
Although this uncontrolled study was not designed to determine clinical response, and the proportion of completed study diaries was low, the mean reduction of seizures/events observed in our cohort compares favourably to KD efficacy, particularly given the super-refractory nature of the population studied, and the fact that seizure documentation was only started as K.Vita was initiated (there was no pre-study baseline recorded). The correlation of seizure/event reduction with plasma concentrations of fatty acids also supports an effect of the diet. Efficacy was observed in a range of seizure types and epilepsy syndromes, similar to those that respond to KDs. Noteworthy improvement was observed in individuals with AHC and in the one patient with GLUT1-DS and associated gait difficulties, who had not had achieved such clinical improvement with previous KD treatment. These findings need to be evaluated further, with consideration of alternative methods of daily recording of seizures/events.

With the exception of isolated cases, participants were not in a state of continued ketosis, typically classified as BHB >1 mmol/l (although definitions range from as low as 0.2 or 0.5 mmol/l), and BHB levels detected were markedly lower than those seen in individuals following a KD. This reduces the risk of hyperketosis and eliminates the often onerous task of daily ketone testing. C8 and C10 plasma levels at visit C were in close agreement with levels observed in patients on the MCT KD and in mouse brains following C10-enriched feeding and in vitro studies with the optimum concentration for mitochondrial proliferation in neuronal-like and fibroblast cell cultures, approximately 250 μM.

The suggested beneficial clinical effect of dietary intervention using K.Vita with low levels or absence of ketosis, supports the putative role of C8 and C10 in enhancing brain-energy metabolism and subsequent

Figure 3 Beta-hydroxybutyrate and medium chain fatty acid levels at baseline and visit C. Plasma beta-hydroxybutyrate and medium chain fatty acid levels measured in participants at both baseline and at visit C: median, interquartile range and range (Left panels in children; Right panels in adults). **P < 0.01, ***P < 0.001, ****P < 0.0001 (Mann–Whitney test).
reduction of seizure activity, probably independent of ketosis. *In vitro* studies have shown that C10, but not C8, increased cellular mitochondrial number in neuronal-like and fibroblast cell cultures, and enhanced mitochondrial respiratory chain activity.\(^\text{11,12}\) C10 alone exhibited antioxidant properties by elevating catalase activity, providing evidence of an additional role of C10 in neuroprotection against oxidative stress. Moreover, C10 but not C8 has been shown to decrease excitatory transmission and to reduce network excitability *in vitro*.\(^\text{9}\) In neurons, C10 is oxidized at about 20% of the rate of C8, and in the presence of C8, C10 oxidation is even further decreased,\(^\text{13}\) suggesting that C8 exerts a sparing effect on C10 catabolism, minimizing its degradation and contributing to the maintenance of brain levels. This is supported by previous work showing beneficial clinical effects of combined octanoic and decanoic acid compared to decanoic acid alone.\(^\text{10}\) The positive correlation of C10 with seizure/event response in our study is consistent with these hypotheses but, due to the clear relationship between C8, C10 and BHB, we cannot rule out that other metabolites also play a role.

**Figure 4** Seizures or paroxysmal events at visits A, B and C. Number of reported seizures or paroxysmal events at visits A, B and C, in 4-week epochs (A in all participants; B in children; C in adults). Analysis is based on *n* = 113 observations from 44 individuals, using linear mixed modelling, adjusting for data source (study diary or physician-documented count) and patient age (adult versus child) as fixed effects, and participant identifier as a random intercept. The reduction between baseline and visit B has a *t*-value of −3.255 (*P* = 0.0015) and the reduction between baseline and visit C has a *t*-value of −4.959 (*P* < 0.0001) (all participants).
Consumption of K.Vita, alongside additional dietary changes, was generally well accepted, tolerated and complied with in our cohort, as long as a flexible approach was taken to introduction and target intake. This study was designed to determine tolerability of a nutritional product rather than primarily to determine effect on seizures or paroxysmal events. Nevertheless, in this group of complex, highly drug-resistant children and adults, we observed a significant reduction in frequency of seizures, or paroxysmal events for some participants, noting that the study was not blinded, nor placebo-controlled. Our findings show promising development for liberalizing dietary management for epilepsy, and clinical resource savings. K.Vita addresses an unmet need for those who cannot access KD services. Further study is warranted; however, in particular, for individuals for whom observance of a KD may prove too challenging and outweigh any clinical benefits, and for specific disorders dependent on a KD, such as GLUT1-DS, and conditions with paroxysmal neurological events, such as AHC, with use of K.Vita alongside minimal dietary modification compared to a traditional KD, as in this study.

Supplementary material

Supplementary material is available at Brain Communications online.

Acknowledgements

We thank all study participants and clinical staff involved in the study implementation, including Mark Elliott and Edwina Saunders from the National Hospital for Neurology and Neurosurgery for assisting with adult study visit assessments, and Allyson Gray, Stephanie Davey, Lauren Holland and Natasha Carroll from GOSH for assisting with children study visit assessments. We also thank the Trial Coordinator, Rumana Jalil.

All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre. This research was also supported by researchers at the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Funding

This study was funded by Vitaflo (International) Ltd.

Competing interests

N.E.S. is supported for a research post by Vitaflo (International) Ltd during the conduct of the study, and has received personal fees from Vitaflo (International) Ltd and Nutricia, outside the submitted work. T.R., E.B., J.M.K., B.L. and T.B. are employees of Vitaflo (International) Ltd. T.R. has a patent ‘Nutritional product’ filed 15/6/2012 (GB 1210699.3) pending. B.L. has a patent (WO2014027023A1) pending. R.S.B.W., S.M.S., S.E., S.J.R.H., J.H.C. and M.C.W. report grants from Vitaflo (International) Ltd during the conduct of the study. J.H.C. also reports honorarium from Nutricia, grants from GW Pharma, Zogenix, Marinus and Ovid outside the submitted work. M.C.W. also reports personal fees from UCB Pharma, Eisai and Sage, outside the submitted work. T.R., R.S.B.W., S.E., S.J.R.H., J.H.C. and M.C.W. have a patent ‘Nutritional product’ filed 10/4/17 (WO2018/189113) pending, and a patent Anticonvulsant compound (WO2016038379A1) pending. All remaining authors have no conflicts of interest.

Appendix

K.Vita Study Group:
Sanjeev Rajakulendran, Aikaterini Vezeyrogloou, Suresh Pujar, Judith Kalser, Christin Eltze, Sophia Varadkar, Robert Robinson, Shamima Rahman.

Titles and affiliations given in Supplementary Material.

References

1. Martin-McGill KJ, Jackson CF, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2018;11:CD001903.
2. Running CA, Mattes RD. Different oral sensitivities to and sensations of short-, medium-, and long-chain fatty acids in humans. Am J Physiol Gastrointest Liver Physiol. 2014;307(3):G381–G389.
3. Clark BJ, House FM. Medium chain triglyceride oil ketogenic diets in the treatment of childhood epilepsy. J Hum Nutr. 1978;32(2):111–116.
4. Liu YM, Wang HS. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets. Biomed J. 2013;36(1):9–15.
5. Boison D. New insights into the mechanisms of the ketogenic diet. Curr Opin Neurol. 2017;30(2):187–192.
6. van Delft R, Lambrechts D, Verschuure P, Hulsman J, Majoie M. Blood beta-hydroxybutyrate correlates better with seizure reduction due to ketogenic diet than do ketones in the urine. Seizure. 2010;19(1):36–39.
7. Schoeler NE, Cross JH, Sander JW, Sisodiya SM. Can we predict a favourable response to Ketogenic Diet Therapies for drug-resistant epilepsy? Epilepsy Res. 2013;106(1-2):1–16.
8. Augustin K, Khabbush A, Williams S, et al. Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol. 2018;17(1):84–93.
9. Chang P, Augustin K, Boddu K, et al. Seizure control by decanonic acid through direct AMPA receptor inhibition. Brain. 2016;139(Pt 2):431–443.
10. Wła P, Socała K, Nieoczym D, et al. Acute anticonvulsant effects of capric acid in seizure tests in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2015;57:110–116.
11. Hughes SD, Kanabus M, Anderson G, et al. The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells. J Neurochem. 2014;129(3):426–433.
12. Kanabus M, Fassone E, Hughes SD, et al. The pleiotropic effects of decanoic acid treatment on mitochondrial function in fibroblasts from patients with complex I deficient Leigh syndrome. J Inherit Metab Dis. 2016;39(3):415–426.
13. Karbassah A, Orford M, Tsai YC, et al. Neuronal decanoic acid oxidation is markedly lower than that of octanoic acid: A mechanistic insight into the medium-chain triglyceride ketogenic diet. Epilepsia. 2017;58(8):1423–1429.
14. R Core Team. R: A language and environment for statistical computing. https://www.R-project.org/. Accessed 18 March 2020.
15. Liu Y-MC. Medium-chain triglyceride (MCT) ketogenic therapy. Epilepsia. 2008;49:33–36.
16. Cai QY, Zhou ZJ, Luo R, et al. Safety and tolerability of the ketogenic diet used for the treatment of refractory childhood epilepsy: A systematic review of published prospective studies. World J Pediatr. 2017;13(6):528–536.
17. Neal EG, Chaffe H, Schwartz RH, et al. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. Epilepsia. 2009;50(5):1109–1117.
18. Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020;6:CD001903.
19. Ye F, Li XJ, Jiang WL, Sun HB, Liu J. Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: A meta-analysis. J Clin Neurol. 2015;11(1):26–31.
20. Klein P, Tyrlıková I, Mathews GC. Dietary treatment in adults with refractory epilepsy: A review. Neurology. 2014;83(21):1978–1985.
21. Lightstone L, Shinnar S, Callahan CM, O’Dell C, Moshe SL, Ballaban-Gil KR. Reasons for failure of the ketogenic diet. J Neurosci Nurs. 2001;33(6):292–295.
22. Neal E. The medium-chain triglyceride ketogenic diet. In: E Neal, ed. Dietary treatment of epilepsy: Practical implementation of ketogenic therapy. Oxford: Wiley-Blackwell; 2012:78–88.
23. Bergqvist AG, Trabulsi J, Schall JJ, Stallings VA. Growth failure in children with intractable epilepsy is not due to increased resting energy expenditure. Dev Med Child Neurol. 2008;50(6):439–444.
24. Carrioz-Moog J, Ladino LD, Benjumea-Cuartas V, et al. Epilepsy, physical activity and sports: A narrative review. Can J Neurol Sci. 2018;45(6):624–632.
25. Shim JS, Oh K, Kim HC. Dietary assessment methods in epidemiologic studies. Epidemiol Health. 2014;36:e2014009.
26. Lord K, Magrath G. Use of the ketogenic diet and dietary practices in the UK. J Hum Nutr Diet. 2010;23(2):126–132.
27. Guerci B, Benichou M, Floriot M, et al. Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients. Diabetes Care. 2003;26(4):1137–1141.
28. Mitchell GA, Kassova-Braintova S, Boukaftane Y, et al. Medical aspects of ketone body metabolism. Clin Invest Med. 1995;18(3):193–216.
29. Haidukewych D, Forsythe WI, Sills M. Monitoring octanoic and decanoic acids in plasma from children with intractable epilepsy treated with medium-chain triglyceride diet. Clin Chem. 1982;28(4 Pt 1):642–645.
30. Sills MA, Forsythe WI, Haidukewych D. Role of octanoic and decanoic acids in the control of seizures. Arch Dis Child. 1986;61(12):1173–1177.
31. Wła P, Socała K, Nieoczym D, et al. Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice. Neuropharmacology. 2012;62(4):1882–1889.